l
[発端となった論文]Unexpected mutations after CRISPR-Cas9 editing
in vivo. Schaefer KA, Wu WH, Colgan DF, Tsang SH, Bassuk AG, Mahajan VB.
(Stanford U & Iowaw U) Nat Methods. 2017 May
30;14(6):547-548
²
(要約)RD1マウスPde6b遺伝子標的;WGSデータをコントロールWGS及びdbSNP/MGP
DB配列と比較、既存オフターゲット解析ソフトで予測されない新規変異(特にSNVs)多数同定;
²
【注】CRISPR Cas9の応用(特に、臨床応用)に不安をいただかせる報告であり、株式市場は直ちにCRISPR技術関連企業株安で反応
l
[CRISPR関連企業・研究者からの反論・反証]
² Gene-Editing
Companies Hit Back at Paper That Criticized CRISPR. Regalado A. MIT Technol Rev. June 9, 2017
² Questioning unexpected
CRISPR off-target mutations in vivo. Kim ST 〜 Kim JS. bioRxiv
Posted June
30, 2017
² “Unexpected mutations after
CRISPR-Cas9 editing in vivo”are most
likely pre-existing sequence variants and not nuclease-induced mutations.
Lareau C, Clement K, Hsu JY, Pattanayak V, Joung
JK, Aryee MJ, Pinello L. bioRxiv Posted July 5, 2017.
² A reanalysis of Schaefer
et al. does not indicate extensive CRISPR/Cas9 mediated off-target editing.
Lescarbeau RM, Murray BA, Barnes TM, Bermingham N. bioRxiv Posted July 6, 2017.
²
CRISPR gene editing technique is probably safe, study
confirms. Michael Le Page. New Scientist 6
July 2017.
コメント